Own Pain Relief Solution Store In Your City | Franchise Sales & Distribution Call us on 8691006638
Rapid thrombolytic intervention is essential in emergency and critical care settings, particularly in life-threatening conditions where immediate restoration of blood flow is required. Fibrinolytic therapy plays a key role in improving survival outcomes in acute cardiovascular events.
KINASERA® (Streptokinase Injection) is developed by RAWIA INTERNATIONAL HEALTHCARE (RIHCA) in collaboration with leading pharmaceutical manufacturing partners and marketed through RAWIACARE. The 1,500,000 IU strength is designed for high-intensity thrombolytic therapy, supporting healthcare professionals in delivering rapid and effective clot dissolution in emergency and critical care environments — To Share • To Care • To Inspire.
| Specifications Table | |
| Parameter | Details |
| Brand Name | KINASERA® |
| Generic Name | Streptokinase |
| Arabic Name | كيناسيرا ستربتوكيناز |
| Category | Thrombolytics |
| Therapeutic Area | Fibrinolytic Therapy |
| Dosage Form | Vial Injection |
| Strength | 1,500,000 IU |
| Volume | 1 Vial |
| Route / Type | Injectable |
| Developed By | RIHCA |
| Platform Name | RAWIACARE / RAWIACARE GLOBAL |
| Acute Myocardial Infarction (Heart Attack) |
| Pulmonary Embolism (PE) |
| Deep Vein Thrombosis (DVT) |
| Emergency thrombolytic therapy |
| Critical care cardiovascular management |
| It is used for emergency thrombolytic therapy in acute cardiovascular conditions. |
| It provides a higher and faster thrombolytic effect for critical situations. |
| Emergency departments, ICU, and cardiac care units. |
| Yes, strict medical supervision is required. |
| 750,000 IU, 1,500,000 IU |
